Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Genmab price target lowered to DKK 2,600 from DKK 2,880 at UBS » 15:58
05/20/22
05/20
15:58
05/20/22
15:58
GMAB

Genmab

$31.06 /

+0.63 (+2.07%)

UBS analyst Laura…

UBS analyst Laura Sutcliffe lowered the firm's price target on Genmab to DKK 2,600 from DKK 2,880 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
GMAB Genmab
$31.06 /

+0.63 (+2.07%)

GMAB Genmab
$31.06 /

+0.63 (+2.07%)

05/13/22 JPMorgan
Genmab price target lowered to DKK 2,700 from DKK 3,100 at JPMorgan
05/13/22 Berenberg
Genmab upgraded to Hold from Sell at Berenberg
05/13/22 Bryan Garnier
Genmab upgraded to Neutral from Sell at Bryan Garnier
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
GMAB Genmab
$31.06 /

+0.63 (+2.07%)

GMAB Genmab
$31.06 /

+0.63 (+2.07%)

Over a week ago
Recommendations
Genmab price target lowered to DKK 2,700 from DKK 3,100 at JPMorgan » 15:09
05/13/22
05/13
15:09
05/13/22
15:09
GMAB

Genmab

$29.21 /

+1.01 (+3.58%)

JPMorgan analyst James…

JPMorgan analyst James Gordon lowered the firm's price target on Genmab to DKK 2,700 from DKK 3,100 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
GMAB Genmab
$29.21 /

+1.01 (+3.58%)

GMAB Genmab
$29.21 /

+1.01 (+3.58%)

05/13/22 Berenberg
Genmab upgraded to Hold from Sell at Berenberg
05/13/22 Bryan Garnier
Genmab upgraded to Neutral from Sell at Bryan Garnier
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
GMAB Genmab
$29.21 /

+1.01 (+3.58%)

GMAB Genmab
$29.21 /

+1.01 (+3.58%)

Upgrade
Genmab upgraded to Hold from Sell at Berenberg » 05:14
05/13/22
05/13
05:14
05/13/22
05:14
GMAB

Genmab

$28.29 /

+0.27 (+0.96%)

Berenberg analyst Xian…

Berenberg analyst Xian Deng upgraded Genmab to Hold from Sell with an unchanged price target of DKK 2,200 post the Q1 results. The analyst sees easing overhangs for the shares with the arbitration with Janssen resolved and "less unfavorable" competition for epcoritamab with Roche's glofitamab continuing to experience delays in filing.

ShowHide Related Items >><<
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

05/13/22 Bryan Garnier
Genmab upgraded to Neutral from Sell at Bryan Garnier
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

Upgrade
Genmab upgraded to Neutral from Sell at Bryan Garnier » 05:11
05/13/22
05/13
05:11
05/13/22
05:11
GMAB

Genmab

$28.29 /

+0.27 (+0.96%)

Bryan Garnier analyst…

Bryan Garnier analyst Victor Floch upgraded Genmab to Neutral from Sell with a DKK 2,100 price target.

ShowHide Related Items >><<
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
03/16/22 UBS
Genmab upgraded to Buy from Neutral at UBS
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

Conference/Events
Genmab management to meet virtually with Truist » 04:55
05/13/22
05/13
04:55
05/13/22
04:55
GMAB

Genmab

$28.29 /

+0.27 (+0.96%)

Virtual Meeting to be…

Virtual Meeting to be held on May 13 hosted by Truist.

ShowHide Related Items >><<
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
03/16/22 UBS
Genmab upgraded to Buy from Neutral at UBS
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

Conference/Events
Genmab management to meet virtually with Truist » 04:55
05/13/22
05/13
04:55
05/13/22
04:55
GMAB

Genmab

$28.29 /

+0.27 (+0.96%)

Virtual Meeting with…

Virtual Meeting with President & CEO van de Winkel, CFO Pagano and CDO Klimovsky to be held on May 13 hosted by Truist.

ShowHide Related Items >><<
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
03/16/22 UBS
Genmab upgraded to Buy from Neutral at UBS
GMAB Genmab
$28.29 /

+0.27 (+0.96%)

GMAB Genmab
$28.29 /

+0.27 (+0.96%)

Earnings
Genmab narrows 2022 revenue view DKK 11B - DKK 12B from DKK 10.8B - DKK 12B » 11:13
05/11/22
05/11
11:13
05/11/22
11:13
GMAB

Genmab

$29.18 /

-0.275 (-0.93%)

Narrows operating profit…

Narrows operating profit view DKK 3.2B - DKK 4.8B from DKK 3B - DKK 4.8B.

ShowHide Related Items >><<
GMAB Genmab
$29.18 /

-0.275 (-0.93%)

GMAB Genmab
$29.18 /

-0.275 (-0.93%)

05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
03/16/22 UBS
Genmab upgraded to Buy from Neutral at UBS
GMAB Genmab
$29.18 /

-0.275 (-0.93%)

GMAB Genmab
$29.18 /

-0.275 (-0.93%)

Earnings
Genmab reports Q1 revenue DKK 2.1B vs. DKK 1.58B last year » 11:11
05/11/22
05/11
11:11
05/11/22
11:11
GMAB

Genmab

$29.19 /

-0.26 (-0.88%)

Reports Q1 operating…

Reports Q1 operating profit DKK 514M vs. DKK 532M last year. "During the first quarter of 2022, there were continued advancements in our pipeline, including the first patient dosed with DuoBody-CD3xB7H4, the presentation of data from the tisotumab vedotin innovaTV 207 study, and the U.S. Food and Drug Administration granting orphan-drug designation to epcoritamab for the treatment of follicular lymphoma. Together these events help to progress us further in our evolution into a fully integrated biotech innovation powerhouse," said Jan van de Winkel, Ph.D., CEO of Genmab.

ShowHide Related Items >><<
GMAB Genmab
$29.19 /

-0.26 (-0.88%)

GMAB Genmab
$29.19 /

-0.26 (-0.88%)

05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
03/16/22 UBS
Genmab upgraded to Buy from Neutral at UBS
GMAB Genmab
$29.19 /

-0.26 (-0.88%)

Conference/Events
Genmab management to meet virtually with Truist » 07:23
05/11/22
05/11
07:23
05/11/22
07:23
GMAB

Genmab

$29.44 /

+0.28 (+0.96%)

Virtual Meeting to be…

Virtual Meeting to be held on May 13 hosted by Truist.

ShowHide Related Items >><<
GMAB Genmab
$29.44 /

+0.28 (+0.96%)

GMAB Genmab
$29.44 /

+0.28 (+0.96%)

05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
03/16/22 UBS
Genmab upgraded to Buy from Neutral at UBS
GMAB Genmab
$29.44 /

+0.28 (+0.96%)

Conference/Events
Genmab management to meet virtually with Truist » 13:10
05/05/22
05/05
13:10
05/05/22
13:10
GMAB

Genmab

$33.44 /

-0.12 (-0.36%)

Virtual Meeting with…

Virtual Meeting with President & CEO van de Winkel, CFO Pagano and CDO Klimovsky to be held on May 13 hosted by Truist.

ShowHide Related Items >><<
GMAB Genmab
$33.44 /

-0.12 (-0.36%)

GMAB Genmab
$33.44 /

-0.12 (-0.36%)

05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
04/14/22 Barclays
Genmab price target lowered to DKK 3,000 from DKK 3,100 at Barclays
03/16/22 UBS
UBS upgrades Genmab to Buy, says most pipeline now 'free'
03/16/22 UBS
Genmab upgraded to Buy from Neutral at UBS
GMAB Genmab
$33.44 /

-0.12 (-0.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.